Biotech Stock Boosted on Late-Stage Trial Data

The stock has been bouncing off support at the $17 level

Deputy Editor
Dec 9, 2021 at 11:16 AM
facebook twitter linkedin

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is up 4.8% to trade at $21.83, after a late-stage trial of the company's treatment for active lupus nephritis showed sustained efficacy and a favorable risk-benefit profile over a three-year period. The drug, Lupkynis, is approved by the U.S. Food and Drug Administration (FDA) in combination with a background immunosuppressive therapy regimen to treat patients with the kidney disorders.
Following its Nov. 3 13-year peak of $33.97, AUPH dropped 43% last month, partially due to its mid-November bear gap after the company filed for a $250 million mixed shelf offering. However, the 160-day moving average provided a floor at the $17 level, and the equity has recently bounced off that level -- on track for its fourth-straight daily win.
Of the eight analysts in coverage, six carry a "buy" or better rating on AUPH, with two at a tepid "hold." Plus, the 12-month consensus price target of $32 is a roughly 50% premium to current levels.
It's also worth noting that while short interest has been falling off, down 37.7% during the two most recent reporting periods, it still represents 8.9% of the stock's available float. 

Meanwhile, AUPH ranks low on the Schaeffer's Volatility Scorecard (SVS), with a score of just 15 out of 100. In other words, the security has consistently realized lower volatility than its options have priced in, making the stock a potential premium-selling candidate.




Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!